March 6th 2021, 6:15pm
According to new research, 88% of trials initially matched to patients were eventually classified as false positives when manually screened by a provider.
March 5th 2021, 3:30pm
The FDA has granted full approval to lorlatinib, expanding its indication to include frontline treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.
February 17th 2021, 7:00pm
ACCC president Randall Oyer, MD, gives insight into the ongoing collaboration between the ACCC and ASCO to foster minority participation in cancer clinical trials.
February 16th 2021, 9:00pm
Excitement around gene therapy is back and greater than before. Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cancer cures will follow.
February 3rd 2021, 11:00pm
Tepmetko (tepotinib) was FDA approved for the treatment of adult patients with metastatic non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
December 28th 2020, 2:00pm
A report published by the Personalized Medicine Coalition shows that the number of personalized medicines on the market grew at the highest rate ever recorded by the organization from 2016-2020.
December 27th 2020, 3:00pm
During the panel on precision medicine at the Quality Cancer Care Alliance (QCCA) Fall Leadership Summit, the speakers discussed testing every patient upfront with a broad molecular assessment and bringing clinical research to the patient.
December 27th 2020, 11:30am
A top-5 roundup of some of 2020's advancements in the precision oncology space.
December 22nd 2020, 7:40pm
A report published by the Personalized Medicine Coalition (PMC) shows that the number of personalized medicines on the market is growing at the highest rate ever recorded by the organization.
December 20th 2020, 11:00am
Managing the constantly evolving selection of therapies in oncology can be difficult, but is of the utmost importance to get the right treatment to the right patient, agreed a panel at Patient-Centered Oncology Care® 2020.
